INS and neoplasm: Hyperglycemia is also a common side effect, resulting not only from impaired insulin secretion from normal pancreatic cells and increased insulin resistance (31), but also through the specific suppression of pathologic insulin secretion from tumor cells in insulinoma patients (32–35).